1 Grenoble Alpes University Hospital, Pharmacovigilance Departement, Grenoble, France.
2 University Grenoble Alpes, HP2 Laboratory, Saint-Martin-d'Heres, France.
3 Grenoble Alpes University Hospital, Pharmacovigilance Department, Grenoble, France.
4 INSERM UMR_S999, Pulmonary Hypertension: Pathophysiology and Novel Therapies» (HPPIT), Le Plessis Robinson, Île-de-France, France.
5 Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, Île-de-France, France.
6 Assistance Publique - Hopitaux de Paris, Department of Respiratory and Intensive Care Medicine, ERN-LUNG, Hôpital Bicêtre, Le Kremlin-Bicêtre, Île-de-France, France.
7 Assistance Publique - Hopitaux de Paris, Department of Pharmacy, Hôpital Bicêtre, Le Kremlin-Bicêtre, Île-de-France, France.
8 Université Paris-Saclay, Faculty of Pharmacy, Orsay, Île-de-France, France.
9 Grenoble Alpes University Hospital, Pharmacovigilance Department, Grenoble, Rhône-Alpes , France.
10 University Grenoble Alpes, HP2 Laboratory, Saint-Martin-d'Heres, France; ckhouri@chu-grenoble.fr.